**This article has been corrected:** In [Table 1](#T1){ref-type="table"}, a unit of measurement is displayed incorrectly. "μM" is used instead of "nM". The corrected [Table 1](#T1){ref-type="table"} is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
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###### IC~50~Values of CDK4/6 Inhibitors

  Cell line   Cancer type   Dominant CDK   Ribociclib IC~50~, mean ± SD, nM   Palbociclib IC~50~, mean ± SD, nM   Abemaciclib IC~50~, mean ± SD, nM
  ----------- ------------- -------------- ---------------------------------- ----------------------------------- -----------------------------------
  JeKo-1      MCL           CDK4           143 ± 87                           72 ± 33                             20 ± 9
  CAMA-1      ER+ BC        CDK4           162 ± 59                           50 ± 24                             28 ± 2
  MCF-7       ER+ BC        CDK4           62 ± 30                            30 ± 18                             11 ± 7
  T47D        ER+ BC        CDK4           111 ± 14                           66 ± 19                             13 ± 3
  REH         ALL           CDK6           1030 ± 246                         60 ± 17                             72 ± 6
  SEM         ALL           CDK6           1484±215                           87 ± 28                             162 ± 37
  Pfeiffer    DLBCL         CDK6           948 ± 53                           89 ± 32                             66 ± 25
  MOLM-13     AML           CDK6           365 ± 62                           47 ± 25                             57 ± 21

IC~50~values (mean ± SD) of ribociclib, palbociclib, and abemaciclib were determined using the CyQuant cell proliferation assay. The average differential for CDK4 versus CDK6 dependent lines for ribociclib, palbociclib, and abemaciclib is 8.0-, 1.3-, and 5.5-fold, respectively. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, breast cancer; CDK, cyclin-dependent kinase; DLBCL, diffuse large B-cell lymphoma; ER+, estrogen receptor-positive; IC~50~, half-maximal inhibitory concentration; MCL, mantle-cell lymphoma; SD, standard deviation.
